By Dennis Ford, Founder & CEO, LSN
As we head home to our families today, Life Science Nation would like to wish you all a very happy holiday. We’re looking forward to a new year full of further growth in the life science sector, and new connections and dialogues between all sides of the health technology marketplace. Next Phase will return next week with more insights into the year’s fundraising trends; until then, keep warm, and have good cheer.
By Nicholas Civitarese, Research Analyst, LSN
Early stage therapeutics companies have a long road ahead to reach the marketplace, and will require significant investment along their way. The search for development capital is therefore a constant challenge for therapeutics startups.
Life Science Nation is pleased to announce a panel of 5 people with extensive experience in early stage therapeutics for RESI San Francisco on January 12th. Moderated by Dennis Purcell, Founder and Senior Advisor at Aisling Capital, the panel will feature:
This panel will give fundraising entrepreneurs a firsthand look at the strategies used by early stage therapeutic investors to assess companies at the earliest, riskiest stage of development, and will help the audience to position their companies as an attractive investment opportunity.
By registering for RESI San Francisco, you’ll be able to listen to the early stage therapeutic panel live in person. January 12th will be our largest conference yet and provides fundraising entrepreneurs with numerous opportunities to expand their network in the life sciences and to learn more about the fundraising process.
A corporate VC firm based in Asia is focused on aggregating technologies in women’s health. The firm invests from an evergreen fund and is a multi-stage investor. Typical investments range from USD 1-5 million, but the fund may make larger tranched investments in the case of therapeutic opportunities. The firm invests in companies worldwide and can act as either a lead investor or co-investor.
The firm is currently focused on building a cluster of technologies in women’s health, across the therapeutic, medical device, diagnostic and healthcare IT sectors. The firm is particularly interested in reproductive health, triple-negative breast cancer, and ovarian cancer, but will consider any opportunity in women’s health. The firm will invest in technologies at any stage of development, including very early-stage technologies. In the medtech space, the firm has a preference for 510k pathways but will look at PMA opportunities if the technology is sufficiently interesting.
The firm may or may not take a board seat in a portfolio company. If a company is seeking to expand into Asia, the firm can leverage the capabilities of its parent company to help companies with global distribution and scale up.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
An early-stage seed fund based in Palo Alto, CA focuses on seed stage and sometimes Series A investments. Typical equity allocations range from $500 – 750 K per company. The firm is open to both leading and co-investing. The firm has been investing from a $50M fund and is currently raising a new fund, from which it expects to make new investments. The firm is seeking opportunities from across the US with a focus on the Bay Area.
The firm invests across multiple industries including healthcare IT. The firm prefers products that do not require FDA approval. Within healthcare IT, the firm considers both consumer-facing and enterprise solutions that demonstrate customer traction and large market potential.
The firm can work with incomplete management teams and would require a board seat on a case-by-case basis. The firm has funded companies in which the founders were either current students or recent graduates from top US universities.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
A venture capital firm based in the Mountain West has approximately $300 million in total assets available for investment. The firm typically makes equity investments in 3 to 4 companies every year, and it has flexibility in terms of capital structures. The average first investment in a company is $2 million- $3 million, though it can invest more or less, depending on the opportunity. The firm prefers to invest in seed and series A (early-stage) companies as an initial investment in a company, though it sometimes makes a first investment in a series B or C round. The firm primarily invests in US-based companies, but it will also consider global companies with a US presence.
The firm is currently looking for investment opportunities in medical devices, biopharma and diagnostics. The firm generally makes investments in product-focused companies in pre-clinical stages with prototypes or other available proof-of-concept work completed. It generally likes to invest in companies that can reach the market with the capital raised from this round of financing. The firm prefers device companies with a 510(k) pathway for regulatory approval, and it will opportunistically consider companies with PMA devices.
The firm seeks to invest in small, early-stage companies with a lean but strong and qualified management / execution team.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
A Chicago-based VC firm is investing from a $250m fund, and is interested in a variety of sectors including the life science field. For life science investments, the firm typically allocates $2-15 million, and prefers to invest in Series B-C rounds. The firm invests in the USA and Canada.
The firm is presently focused on technologies that involve an IT/software component, across the medical devices, diagnostics, and healthcare services sectors in addition to pure digital health opportunities. The firm is open to opportunities in any clinical indication. The firm is only interested in devices and diagnostics that have in-human data.
In the life science sector, the firm is not interested in early-stage opportunities; however the firm is open to both companies with an approved product on the market, and companies with a product in late-stage clinical trials. The firm takes the strength of the management team into consideration.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
By Dennis Ford, Founder & CEO, LSN
The RESI Innovation Challenge received a record number of applicants this fall. LSN’s scientific review board assessed and ranked all entrants across a wide range of criteria, from scientific novelty to strength of IP, to select the 30 strongest entrants. We’d now like to announce these successful applicants. These entrepreneurs have been selected by LSN’s scientific validation team to receive a presentation space in the exhibit hall for the full day of the conference to showcase their innovations to investors and fellow entrepreneurs. We’re excited to meet all these companies in person in the Exhibitor Hall at RESI, and we hope you’ll join us there to vote for the very best of these cutting-edge life science startups.
Next Phase Newsletter 